Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Observational, Secondary Data Collection, Retrospective, National Study to Assess the Prevalence of HER2-low Breast Cancer Among Patients Previously Diagnosed With Unresectable and/or Metastatic HER2-Negative Breast Cancer in Egypt - UNFOLD

NCT06188494 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06188494
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06188494 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Observational, Secondary Data Collection, Retrospective, National Study to Assess the Prevalence of HER2-low Breast Cancer Among Patients Previously Diagnosed With Unresectable and/or Metastatic HER2-Negative Breast Cancer in Egypt - UNFOLD
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
May 13, 2024
Completion date
September 16, 2024
Enrollment
405 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer